| Autor: |
Ionac I; Doctoral School Medicine-Pharmacy, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania., Lazar MA; Department VI Cardiology-Cardiology Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania., Hoinoiu T; Department V, 1st Internal Medicine, Discipline of Clinical Practical Skills, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.; Advanced Cardiology and Hemostaseology Research Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania., Crisan S; Doctoral School Medicine-Pharmacy, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.; Department VI Cardiology-Cardiology Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania., Pescariu SA; Department VI Cardiology-Cardiovascular Surgery Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babeș' University of Medicine and Pharmacy from Timișoara, No. 2 Eftimie Murgu Square, 300041 Timișoara, Romania., Dima CN; Department VI Cardiology-Cardiovascular Surgery Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babeș' University of Medicine and Pharmacy from Timișoara, No. 2 Eftimie Murgu Square, 300041 Timișoara, Romania., Luca CT; Doctoral School Medicine-Pharmacy, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.; Department VI Cardiology-Cardiology Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.; Research Center of the Institute of Cardiovascular Diseases Timișoara, 'Victor Babeș' University of Medicine and Pharmacy from Timișoara, No. 2 Eftimie Murgu Square, 300041 Timișoara, Romania., Mornos C; Doctoral School Medicine-Pharmacy, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.; Department VI Cardiology-Cardiology Clinic, Institute for Cardiovascular Diseases of Timișoara, 'Victor Babes' University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.; Research Center of the Institute of Cardiovascular Diseases Timișoara, 'Victor Babeș' University of Medicine and Pharmacy from Timișoara, No. 2 Eftimie Murgu Square, 300041 Timișoara, Romania. |
| Abstrakt: |
It has been shown that patients with NYHA class I and II have a high morbidity and mortality burden. We investigated the value of a new tissue Doppler index, E/(e' × s'), to predict cardiac events in the long-term follow-up of patients at an early stage of heart failure (HF). Sequential echocardiography was conducted on a consecutive cohort of 212 hospitalized HF patients, pre-discharged and with three-month follow-up. The primary end point consisted of cardiac death or readmission due to HF worsening. During follow-up, cardiac events occurred in 99 patients (46.7%). The first cardiac event was represented by cardiac death in 8 patients (3.8%) and readmission for HF in 91 patients (42.9%). A Kaplan-Meier analysis did not show a significantly different event-free survival rate between patients with NYHA class I and II. The composite end point was significantly higher in patients with an E/(e' × s') >1.6. The E/(e' × s') at discharge was the best independent predictor of cardiac events. Those exhibiting an E/(e' × s') > 1.6 at discharge, with a subsequent deterioration after three months, displayed the poorest prognosis concerning cardiac events, HF-related rehospitalization, and cardiac mortality (all p < 0.05). In early-stage HF patients, an E/(e' × s') > 1.6 emerged as a robust predictor of clinical outcomes, especially when coupled with a deterioration in condition. |
